[重度过敏性哮喘患者中奥马珠单抗治疗的疾病修饰作用及治疗持续时间]
[Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
作者信息
Schreiber J, Kopp M V, Korn S, Taube C, Buhl R
机构信息
Universitätsklinikum der Otto-von-Guericke-Universität Magdeburg, Abteilung für Pneumologie.
Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Kinder- und Jugendmedizin, Pädiatrische Pneumologie und Allergologie, Airway Research Center North (ARCN), Mitglied des Deutschen Zentrums für Lungenforschung (DZL).
出版信息
Pneumologie. 2014 Mar;68(3):187-92. doi: 10.1055/s-0033-1359242. Epub 2014 Jan 29.
BACKGROUND AND METHODS
Omalizumab is a monoclonal anti-IgE-antibody that is used to treat severe allergic asthma. The aim of this review was to evaluate the available evidence in a panel of experts and to provide recommendations on therapy duration with omalizumab.
RESULTS
A direct or indirect interaction between omalizumab and IgE production seems likely. Pharmacokinetic-pharmakodynamic models suggest that omalizumab modulates IgE production. This hypothesis is currently investigated in clinical studies. In addition, available evidence suggests that omalizumab mitigates different factors of airway remodeling. However, based on the currently available data, no recommendations can be given in regard to reduction of dosage or discontinuation of omalizumab in long term treated patients.
CONCLUSIONS
Currently, neither dose reductions nor treatment withdrawal can be recommended in patients with severe allergic asthma and long term treatment with omalizumab. Clinical studies addressing these issues are being conducted.
背景与方法
奥马珠单抗是一种用于治疗重度过敏性哮喘的单克隆抗IgE抗体。本综述的目的是评估一组专家的现有证据，并就奥马珠单抗的治疗疗程提供建议。
结果
奥马珠单抗与IgE产生之间似乎存在直接或间接相互作用。药代动力学-药效学模型表明奥马珠单抗可调节IgE产生。这一假说目前正在临床研究中进行调查。此外，现有证据表明奥马珠单抗可减轻气道重塑的不同因素。然而，基于目前可得的数据，对于长期接受治疗的患者，无法给出关于减少奥马珠单抗剂量或停药的建议。
结论
目前，对于重度过敏性哮喘且长期使用奥马珠单抗治疗的患者，既不建议减少剂量，也不建议停药。针对这些问题的临床研究正在进行。
Zotero 插件